Lite Strategy Raises $100M for Litecoin Treasury Strategy

Lite Strategy, Inc. (NASDAQ: LITS) has raised $100 million via a July 2025 private placement to support its newly launched Litecoin Treasury Strategy. The funding enabled the purchase of 929,548 LTC tokens, making LITS the first U.S.-listed company to hold Litecoin as a primary reserve. Under the Litecoin Treasury Strategy, Lite Strategy has rebranded from MEI Pharma, updated its ticker to LITS and partnered with GSR to manage governance and execution. The firm appointed Litecoin founder Charlie Lee and GSR’s Joshua Riezman to its board to oversee its Litecoin reserves. To capitalize on its near-million LTC holding, Lite Strategy announced a $25 million share repurchase program, transitioning from accumulation to active capital market operations. As of September 30, 2025, the company reported $12.21 million in working capital and zero debt. It also continues to evaluate its remaining pharmaceutical assets, including preclinical research for voruciclib and licensing opportunities for zandelisib. The Litecoin Treasury Strategy aims to enhance shareholder value by offering direct institutional exposure to Litecoin and leveraging market-driven initiatives.